Enanta Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Presentation to be Webcast on January 14 at 11:00 A.M. PT

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview that will include an update on Enanta’s development pipeline, including preclinical data from Enanta’s new research program in non-alcoholic steatohepatitis (NASH), on January 14, 2015 at 11:00 a.m. PT during the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco.

A live webcast and replay of the presentation, as well as of the question and answer breakout session that follows the presentation, can be accessed by visiting the “Calendar of Events” section on the “Investors” page of Enanta’s website at www.enanta.com. The replay webcast will be available following the presentation and will be archived for approximately 60 days.

About EnantaEnanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A, and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Enanta’s lead protease inhibitor, paritaprevir, is part of AbbVie’s recently approved HCV treatment regimen. In addition, Enanta has a preclinical program in non-alcoholic steatohepatitis, or NASH, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver.

Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli, [e-mail]